Nosis Bio

Nosis Bio is an AI-driven biotech pioneering a novel platform, Connexa, to design and deliver cell-specific RNA therapeutics. The platform leverages a proprietary 'receptome atlas' and AI models to discover novel targetable receptors and design optimized ligand-payload combinations, aiming to rapidly advance programs from discovery to in vivo validation. The company has a preclinical pipeline focused on fibrosis, immunology, and inflammatory diseases, and has secured a strategic collaboration with Johnson & Johnson in neurology, positioning it to expand RNA medicine beyond the liver and muscle.

Connexa Platform: An integrated system using a proprietary receptome atlas, physics-aware deep learning AI for atom-level drug design, and an in vivo-integrated validation workflow to discover and develop receptor-targeted RNA medicines for specific cell types.

Nosis Bio competes in the rapidly evolving field of targeted RNA delivery, facing competition from companies developing novel lipid nanoparticles (LNPs), GalNAc and other conjugate technologies, and peptide-based delivery systems. Its key differentiation is the integrated AI-driven platform focused on receptor-specific targeting and early in vivo validation, aiming to systematically overcome the empirical nature of the field.